Carbon ion beam radioresistant rodent cells are sensitized to trifluorothymidine exposure

Baek,Sung‑Jae; Sato,Katsutoshi; Nishida,Naohiro; Koseki,Jun; Hayashi,Kazuhiko; Kawamoto,Koichi; Konno,Masamitsu; Doki,Yuichiro; Mori,Masaki; Ogawa,Kazuhiko; Ishii,Hideshi

doi:10.3892/ol.2018.9004

Carbon ion beam radioresistant rodent cells are sensitized to trifluorothymidine exposure

Authors:
- Sung‑Jae Baek
- Katsutoshi Sato
- Naohiro Nishida
- Jun Koseki
- Kazuhiko Hayashi
- Koichi Kawamoto
- Masamitsu Konno
- Yuichiro Doki
- Masaki Mori
- Kazuhiko Ogawa
- Hideshi Ishii
View Affiliations

Affiliations: Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan, National Institute for Radiological Science, Chiba 263‑8555, Japan, Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan, Department of Cancer Profiling Discovery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan
Published online on: June 21, 2018 https://doi.org/10.3892/ol.2018.9004
Pages: 3389-3393

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although charged particle therapy, including carbon ion beam radiation, is a cutting‑edge technology in human cancer treatment, the molecular mechanisms underlying cellular resistance to this type of therapy remain unknown. Furthermore, the chemotherapeutic agents that are most effective at overcoming cellular resistance remain unknown. In the present study, carbon ion beam radioresistant rodent cells were developed and their sensitization to trifluorothymidine (FTD), a derivative of deoxythymidine, was studied. The results of the present study demonstrated that carbon ion beam radioresistant cells were more sensitive to FTD compared with X‑ray radioresistant cells. The results of the present study suggested that FTD is involved in carbon ion beam radioresistance, encouraging further study of cellular resistance to charged particle therapy for refractory human cancer.

View Figures

View References

1	Kamada T, Tsujii H, Blakely EA, Debus J, De Neve W, Durante M, Jäkel O, Mayer R, Orecchia R, Pötter R, et al: Carbon ion radiotherapy in Japan: An assessment of 20 years of clinical experience. Lancet Oncol. 16:e93–e100. 2015. View Article : Google Scholar : PubMed/NCBI
2	Yasueda A, Urushima H and Ito T: Efficacy and interaction of antioxidant supplements as adjuvant therapy in cancer treatment: A systematic review. ntegr. Integr Cancer Ther. 15:17–39. 2016. View Article : Google Scholar : PubMed/NCBI
3	Skvortsova I, Debbage P, Kumar V and Skvortsov S: Radiation resistance: Cancer stem cells (CSCs) and their enigmatic pro-survival signaling. Semin Cancer Biol. 35:39–44. 2015. View Article : Google Scholar : PubMed/NCBI
4	Baek SJ, Ishii H, Tamari K, Hayashi K, Nishida N, Konno M, Kawamoto K, Koseki J, Fukusumi T, Hasegawa S, et al: Cancer stem cells: The potential of carbon ion beam radiation and new radiosensitizers (Review). Oncol Rep. 34:2233–2237. 2015. View Article : Google Scholar : PubMed/NCBI
5	Kunkel TA: DNA replication fidelity. J Biol Chem. 279:16895–16898. 2004. View Article : Google Scholar : PubMed/NCBI
6	Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, et al: CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 120:3326–3339. 2010. View Article : Google Scholar : PubMed/NCBI
7	Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes Tumor Growth. Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI
8	Wada T, Ishimoto T, Seishima R, Tsuchihashi K, Yoshikawa M, Oshima H, Oshima M, Masuko T, Wright NA, Furuhashi S, et al: Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia. Cancer Sci. 104:1323–1329. 2013. View Article : Google Scholar : PubMed/NCBI
9	Peters CJ: Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies. Ther Adv Med Oncol. 7:340–356. 2015. View Article : Google Scholar : PubMed/NCBI
10	Uhl M, Herfarth K and Debus J: Comparing the use of protons and carbon ions for treatment. Cancer J. 20:433–439. 2014. View Article : Google Scholar : PubMed/NCBI
11	Cui X, Oonishi K, Tsujii H, Yasuda T, Matsumoto Y, Furusawa Y, Akashi M, Kamada T and Okayasu R: Effects of carbon ion beam on putative colon cancer stem cells and its comparison with X-rays. Cancer Res. 71:3676–3687. 2011. View Article : Google Scholar : PubMed/NCBI
12	Ishikawa H, Tsuji H, Kamada T, Akakura K, Suzuki H, Shimazaki J and Tsujii H: Working Group for Genitourinary Tumors: Carbon-ion radiation therapy for prostate cancer. Int J Urol. 19:296–305. 2012. View Article : Google Scholar : PubMed/NCBI
13	Tsujii H and Kamada T: A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol. 42:670–685. 2012. View Article : Google Scholar : PubMed/NCBI
14	Nakano T, Suzuki Y, Ohno T, Kato S, Suzuki M, Morita S, Sato S, Oka K and Tsujii H: Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin Cancer Res. 12:2185–2190. 2006. View Article : Google Scholar : PubMed/NCBI
15	Mizoe JE, Hasegawa A, Jingu K, Takagi R, Bessyo H, Morikawa T, Tonoki M, Tsuji H, Kamada T, Tsujii H, et al: Results of carbon ion radiotherapy for head and neck cancer. Radiother Oncol. 103:32–37. 2012. View Article : Google Scholar : PubMed/NCBI
16	Jingu K, Tsujii H, Mizoe JE, Hasegawa A, Bessho H, Takagi R, Morikawa T, Tonogi M, Tsuji H, Kamada T and Yamada S: Organizing Committee for the Working Group for Head-and-Neck Cancer: Carbon ion radiation therapy improves the prognosis of unresectable adult bone and soft-tissue sarcoma of the head and neck. Int J Radiat Oncol Biol Phys. 82:2125–2131. 2012. View Article : Google Scholar : PubMed/NCBI
17	Sato K, Imai T, Okayasu R and Shimokawa T: Heterochromatin domain number correlates with x-ray and carbon-ion radiation resistance in cancer cells. Radiat Res. 182:408–419. 2014. View Article : Google Scholar : PubMed/NCBI
18	Chandel NS: Evolution of Mitochondria as Signaling Organelles. Cell Metab. 22:204–206. 2015. View Article : Google Scholar : PubMed/NCBI
19	Temmink OH, Emura T, de Bruin M, Fukushima M and Peters GJ: Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci. 98:779–789. 2007. View Article : Google Scholar : PubMed/NCBI
20	Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015. View Article : Google Scholar : PubMed/NCBI